Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
Journal of Radiation Research · 20.01.2023 · 64 (1) · 142-153
DOI: 10.1093/jrr/rrac057 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Radiation Research, online erschienen am 22.09.2022. Verfasst von Noriko Kishi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kyoto Radiation Oncology Study Group.
Abstract (Originalsprache)
Chemoradiotherapy followed by consolidation durvalumab (CCRT+D) improves survival in patients with stage III non-small-cell lung cancer (NSCLC). We compared recurrence patterns and survival in the CCRT+D and CCRT cohorts. We conducted a multicenter, retrospective study in Japan. Patients who received CCRT for stage III NSCLC were included in this study. Of 178 eligible patients, 136 were in the CCRT+D and 42 were in the CCRT cohorts. Locoregional recurrence (LR), LR plus distant metastases (DM), and DM were observed in 20.6%, 8.8%, 27.9% of the CCRT+D, and 26.2%, 16.7% and 33.3% of the CCRT cohorts, respectively. In-field recurrence was the most common LR pattern in both cohorts. Squamous cell carcinoma and PD-L1 expression < 1%, and female sex and EGFR mutations were significantly associated with an increased risk of LR and DM. In patients with any risk factors for LR, the incidence of LR was similar in the CCRT+D and CCRT (39.5% vs 45.5%). The 24 month progression-free survival (PFS) and overall survival (OS) were 40.3% and 69.4% in the CCRT+D and 24.7% and 61.0% in the CCRT cohorts, respectively. Poor performance status and no consolidation durvalumab were significantly associated with shorter PFS. There was a significant difference in PFS between the CCRT+D and CCRT in the propensity score-matched cohort (HR = 0.51, P = 0.005). In conclusion, consolidation durvalumab decreased both LR and DM, and significantly improved PFS. However, in-field recurrence was still a major problem, as well as DM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
- Department of Radiology, Japanese Red Cross Fukui Hospital, 2-4-1 Tsukimi, Fukui, 918-8501, Japan.
- Department of Radiation Oncology, Kishiwada City Hospital, 1001 Gakuhara-cho, Kishiwada, Osaka, 596-8501, Japan.
- Department of Radiation Oncology, Kobe City Medical Center General Hospital, 2-1-1, Minatojimaminamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan.
- Department of Radiology, National Hospital Organization Kyoto Medical Center, 1-1 Fukakusamukaihata-cho, Fushimi-ku, Kyoto, 612-8555, Japan.
- Department of Radiation Oncology, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki, Okayama, 710-8602, Japan.
Förderung
- Kyoto Radiation Oncology Study Group
Zitieren
APA
Kishi, N., Matsuo, Y., Shintani, T., Ogura, M., Mitsuyoshi, T., Araki, N., Fujii, K., Okumura, S., Nakamatsu, K., Kishi, T., Atsuta, T., Sakamoto, T., Ohtsu, S., Katagiri, T., Narabayashi, M., Fujishiro, S., Iizuka, Y., Ozasa, H., Hirai, T., …, & Kyoto Radiation Oncology Study Group (KROSG) (2023). Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. Journal of Radiation Research, 64(1), 142-153. https://doi.org/10.1093/jrr/rrac057
Vancouver
Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, et al. Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. Journal of Radiation Research. 2023;64(1):142-153. doi:10.1093/jrr/rrac057
BibTeX
@article{Kishi2023,
author = {Kishi, Noriko and Matsuo, Yukinori and Shintani, Takashi and Ogura, Masakazu and Mitsuyoshi, Takamasa and Araki, Norio and Fujii, Kota and Okumura, Setsuko and Nakamatsu, Kiyoshi and Kishi, Takahiro and Atsuta, Tomoko and Sakamoto, Takashi and Ohtsu, Shuji and Katagiri, Tomohiro and Narabayashi, Masaru and Fujishiro, Satsuki and Iizuka, Yusuke and Ozasa, Hiroaki and Hirai, Toyohiro and Mizowaki, Takashi and Kyoto Radiation Oncology Study Group (KROSG), Kyoto Radiation Oncology Study Group (KROSG)},
title = {Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer},
journal = {Journal of Radiation Research},
year = {2023},
volume = {64},
number = {1},
pages = {142--153},
doi = {10.1093/jrr/rrac057}
}
EUVIMED